MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.radonc.2018.09.019

Медицинская библиотека · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2018

The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).

van Diessen Judi, De Ruysscher Dirk, Sonke Jan-Jakob, Damen Eugène, Sikorska Karolina, Reymen Bart, van Elmpt Wouter, Westman Gunnar, Fredberg Persson Gitte, Dieleman Edith, Bjorkestrand Hedvig, Faivre-Finn Corinne, Belderbos José

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: The PET-boost randomized phase II trial (NCT01024829) investigated dose-escalation to the entire primary tumour or redistributed to regions of high pre-treatment FDG-uptake in inoperable non-small cell lung cancer (NSCLC) patients. We present a toxicity analysis of the 107 patients randomized in the study.

MATERIALS AND

METHODS

Patients with stage II-III NSCLC were treated with an isotoxic integrated boost of ≥72 Gy in 24 fractions, with/without chemotherapy and strict dose limits. Toxicity was scored until death according to the CTCAEv3.0.

RESULTS

77 (72%) patients were treated with concurrent chemoradiotherapy. Acute and late ≥G3 occurred in 41% and 25%. For concurrent (C) and sequential or radiotherapy alone (S), the most common acute ≥G3 toxicities were: dysphagia in 14.3% (C) and 3.3% (S), dyspnoea in 2.6% (C) and 6.7% (S), pneumonitis in 0% (C) and 6.7% (S), cardiac toxicity in 6.5% (C) and 3.3% (S). Seventeen patients died of which in 13 patients a possible relation to treatment could not be excluded. In 10 of these 13 patients progressive disease was scored. Fatal pulmonary haemorrhages and oesophageal fistulae were observed in 9 patients.

CONCLUSION

Personalized dose-escalation in inoperable NSCLC patients results in higher acute and late toxicity compared to conventional chemoradiotherapy. The toxicity, however, was within the boundaries of the pre-defined stopping rules.

Для цитирования: van Diessen Judi, De Ruysscher Dirk, Sonke Jan-Jakob, Damen Eugène, Sikorska Karolina, Reymen Bart, van Elmpt Wouter, Westman Gunnar, Fredberg Persson Gitte, Dieleman Edith, Bjorkestrand Hedvig, Faivre-Finn Corinne, Belderbos José. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018. DOI: 10.1016/j.radonc.2018.09.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.